COVID, flu, RSV: how these common viruses are tracking this winter – and how to protect yourself
Last week, non-urgent surgeries were paused in several Queensland hospitals due to a surge of influenza and COVID cases filling up hospital beds.
Meanwhile, more than 200 aged care facilities around Australia are reportedly facing COVID outbreaks.
So, just how bad are respiratory infections this year, and which viruses are causing the biggest problems?
COVID
Until May, COVID case numbers were about half last year's level, but June's 32,348 notifications are closing the gap (compared with 45,634 in June 2024). That said, we know far fewer people test now than they did earlier in the pandemic, so these numbers are likely to be an underestimate.
According to the latest Australian Respiratory Surveillance Report, Australia now appears to be emerging from a winter wave of COVID cases driven largely by the NB.1.8.1 subvariant, known as 'Nimbus'.
Besides classic cold-like symptoms, this Omicron offshoot can reportedly cause particularly painful sore throats as well as gastrointestinal symptoms such as nausea and diarrhoea.
While some people who catch COVID have no symptoms or just mild ones, for many people the virus can be serious. Older adults and those with chronic health issues remain at greatest risk of experiencing severe illness and dying from COVID.
Some 138 aged care residents have died from COVID since the beginning of June.
The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another subvariant in circulation, XFG or 'Stratus' – which means the vaccine should remain effective against current variants.
Free boosters are available to most people annually, while those aged 75 and older are advised to get one every six months.
Vaccination, as well as early treatment with antivirals, lowers the risk of severe illness and long COVID. People aged 70 and older, as well as younger people with certain risk factors, are eligible for antivirals if they test positive.
Influenza
The 2025 flu season has been unusually severe. From January to May, total case numbers were 30% higher than last year, increasing pressure on health systems.
More recent case numbers seem to be trending lower than 2024, however we don't appear to have reached the peak yet.
Flu symptoms are generally more severe than the common cold and may include high fever, chills, muscle aches, fatigue, sore throat and a runny or blocked nose.
Most people recover in under a week, but the flu can be more severe (and even fatal) in groups including older people, young children and pregnant women.
An annual vaccination is available for free to children aged 6 months to 4 years, pregnant women, those aged 65+, and other higher-risk groups.
Queensland and Western Australia provide a free flu vaccine for all people aged 6 months and older, but in other states and territories, people not eligible for a free vaccine can pay (usually A$30 or less) to receive one.
RSV
The third significant respiratory virus, respiratory syncytial virus (RSV), only became a notifiable disease in 2021 (before this doctors didn't need to record infections, meaning data is sparse).
Last year saw Australia's highest case numbers since RSV reporting began. By May, cases in 2025 were lower than 2024, but by June, they had caught up: 27,243 cases this June versus 26,596 in June 2024. However it looks as though we may have just passed the peak.
RSV's symptoms are usually mild and cold-like, but it can cause serious illness such as bronchiolitis and pneumonia. Infants, older people, and people with chronic health conditions are among those at highest risk. In young children, RSV is a leading cause of hospitalisation.
A free vaccine is now available for pregnant women, protecting infants for up to six months. A monoclonal antibody (different to a vaccine but also given as an injection) is also available for at-risk children up to age two, especially if their mothers didn't receive the RSV vaccine during pregnancy.
For older adults, two RSV vaccines (Arexvy and Abrysvo) are available, with a single dose recommended for everyone aged 75+, those over 60 at higher risk due to medical conditions, and all Aboriginal and Torres Strait Islander people aged 60+.
Unfortunately, these are not currently subsidised and cost about $300. Protection lasts at least three years.
The common cold
While viruses including COVID, RSV and influenza dominate headlines, we often overlook one of the most widespread – the common cold.
The common cold can be caused by more than 200 different viruses – mainly rhinoviruses but also some coronaviruses, adenoviruses and enteroviruses.
Typical symptoms include a runny or blocked nose, sore throat, coughing, sneezing, headache, tiredness and sometimes a mild fever.
Children get about 6–8 colds per year while adults average 2–4, and symptoms usually resolve in a week. Most recover with rest, fluids, and possibly over-the-counter medications.
Because so many different viruses cause the common cold, and because these constantly mutate, developing a vaccine has been extremely challenging. Researchers continue to explore solutions, but a universal cold vaccine remains elusive.
How do I protect myself and others?
The precautions we learned during the COVID pandemic remain valid. These are all airborne viruses which can be spread by coughing, sneezing and touching contaminated surfaces.
Practise good hygiene, teach children proper cough etiquette, wear a high-quality mask if you're at high risk, and stay home to rest if unwell.
You can now buy rapid antigen tests (called panel tests) that test for influenza (A or B), COVID and RSV. So, if you're unwell with a respiratory infection, consider testing yourself at home.
While many winter lurgies can be trivial, this is not always the case. We can all do our bit to reduce the impact.
This article is republished from The Conversation. It was written by: Adrian Esterman, University of South Australia
Read more:
Here's why 3-person embryos are a breakthrough for science – but not LGBTQ+ families
Pumped up with poison: new research shows many anabolic steroids contain toxic metals
From painkillers to antibiotics: five medicines that could harm your hearing
Adrian Esterman receives funding from the Medical Research Future Fund.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Magazine
6 minutes ago
- Time Magazine
Trump Administration to Wind Down mRNA Vaccine Development
The U.S. Department of Health and Human Services (HHS) said on Tuesday that it will start winding down mRNA vaccine development efforts under a federal health agency focused on developing medical countermeasures to address public health emergencies. mRNA vaccines have been credited by public health experts with saving millions of lives during the COVID-19 pandemic, and many infectious disease experts have stressed that years of research have shown the shots are both safe and effective. But HHS Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, claimed in a statement accompanying HHS's announcement that 'data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.' The move, which HHS said comes after 'a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency,' will involve canceling and de-scoping various contracts under the Biomedical Advanced Research and Development Authority (BARDA). The 'wind-down' will impact 22 projects that come out to a total of nearly $500 million, according to HHS's press release. 'We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,' Kennedy said. Kennedy has faced widespread criticism from public health experts over the years for spreading medical disinformation, including about vaccines. His nomination by President Donald Trump in November to lead HHS sparked outcry from the science and medical communities, but he was ultimately confirmed to the role in February. Read More: Measles Cases Are at a 33-Year High. Experts Warn Other Diseases Could Follow Tuesday's announcement marks HHS's latest move under Kennedy's leadership to significantly change the country's immunization policy. In May, the Food and Drug Administration (FDA) said that it will stop recommending annual COVID-19 vaccines for children and most adults. In June, Kennedy said that he would be retiring all 17 members of a committee that provides recommendations on vaccines to the Centers for Disease Control and Prevention (CDC). Kennedy appointed new members to the committee, and last month, HHS adopted a controversial recommendation from the panel to remove the preservative thimerosal from flu vaccines, despite extensive research showing it to be safe in the small amounts included in some shots. HHS said on Tuesday that 'some final-stage contracts … will be allowed to run their course to preserve prior taxpayer investment,' but that 'no new mRNA-based projects will be initiated.' The agency said that 'other uses of mRNA technology within the department are not impacted' by the move. It also said that BARDA will shift its focus to 'platforms with stronger safety records and transparent clinical and manufacturing data practices,' adding that "technologies that were funded during the emergency phase but failed to meet current scientific standards will be phased out in favor of evidence-based, ethically grounded solutions - like whole-virus vaccines and novel platforms.'


Bloomberg
36 minutes ago
- Bloomberg
China Revives Covid-Era Health Measures to Prevent Mosquito-Borne Virus
More than two years after ending pandemic emergency procedures, China has revived some Covid-era health controls in the southern Guangdong province to prevent the spread of a painful mosquito-borne viral disease. Recording the identities of people buying commonly used medicines, reinstating mass testing, requiring travel history reports and undertaking community-level disinfection are among measures put in place to check chikungunya, after a city in the industrial hub reported a rare but massive outbreak of the virus this summer.
Yahoo
an hour ago
- Yahoo
Talking therapy for back pain can help patients for up to three years
Talking therapies can reduce pain and disability among people with lower back pain, a new study suggests. And the benefit can be seen for up to three years after treatment, academics found. Psychotherapists use various talking therapies to help people to overcome stress, emotional and relationship problems or troublesome habits. For some, lower back pain will be a single incident which recovers on its own but most people with the condition will suffer long-term problems with unpredictable flare-ups. Most treatments for the condition have 'small to moderate' effects that do not last for a long period of time, experts said, The new study, published in the journal Lancet Rheumatology, focused on a type of psychotherapy called cognitive functional therapy (CFT) – a type of psychotherapy to 'address the causal mechanisms' of chronic lower back pain and help to change the way people think about and respond to pain. An international team of researchers, led by experts in Australia, wanted to examine whether CFT brought long-term benefits for patients with lower back pain. More than 1,000 patients from Australia with lower back pain were recruited to the study. A third were given 'usual care', a third were given CFT and the final third were given CFT plus another technique known as biofeedback, which tries to teach a person to control automatic body functions. People who received 'usual care' were given what their GP surgery recommended or what they chose. Some 300 people with an average age of 48 continued the study to the three-year follow-up point, split between each of the three groups. Researchers found that CFT, and CFT and biofeedback, were both more effective than usual care in reducing activity limitation caused by lower back pain. And they also were more effective for reducing pain intensity at three years. There were no significant differences among patients who did and did not use biofeedback techniques, prompting researchers to say the use of biofeedback 'did not add to effectiveness'. 'Treatment sessions of CFT produced sustained effects at three years for people with chronic disabling low back pain,' the researchers wrote. 'These long-term effects are novel and provide the opportunity to markedly reduce the effect of chronic back pain if the intervention can be widely implemented.' They added: 'CFT is the first treatment for chronic disabling low back pain with good evidence of large, long-term effects on disability. 'It offers a high-value, low-risk intervention with long-term benefits for patients with persistent, disabling low back pain.'